Seneca Growth Capital VCT plc is a fund of Seneca Partners Limited.
Share Price & News
How has Seneca Growth Capital VCT's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SVCT has not had significant price volatility in the past 3 months.
7 Day Return
GB Capital Markets
1 Year Return
GB Capital Markets
Return vs Industry: SVCT underperformed the UK Capital Markets industry which returned 9.7% over the past year.
Return vs Market: SVCT underperformed the UK Market which returned -12.5% over the past year.
Price Volatility Vs. Market
How volatile is Seneca Growth Capital VCT's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Seneca Growth Capital VCT undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SVCT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SVCT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SVCT is unprofitable, so we can't compare its PE Ratio to the Capital Markets industry average.
PE vs Market: SVCT is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SVCT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SVCT is good value based on its PB Ratio (0.5x) compared to the GB Capital Markets industry average (1.6x).
How is Seneca Growth Capital VCT forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Diversified Financials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Seneca Growth Capital VCT has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Seneca Growth Capital VCT performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SVCT is currently unprofitable.
Growing Profit Margin: SVCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SVCT is unprofitable, but has reduced losses over the past 5 years at a rate of 31.2% per year.
Accelerating Growth: Unable to compare SVCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SVCT is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (16.4%).
Return on Equity
High ROE: SVCT has a negative Return on Equity (-8.53%), as it is currently unprofitable.
How is Seneca Growth Capital VCT's financial position?
Financial Position Analysis
Short Term Liabilities: SVCT's short term assets (£3.9M) exceed its short term liabilities (£236.0K).
Long Term Liabilities: SVCT's short term assets (£3.9M) exceed its long term liabilities (£53.0K).
Debt to Equity History and Analysis
Debt Level: SVCT is debt free.
Reducing Debt: SVCT has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SVCT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SVCT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 4.6% each year
What is Seneca Growth Capital VCT's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SVCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SVCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SVCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SVCT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: SVCT is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SVCT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Seneca Growth Capital VCT has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.5%.
Seneca Growth Capital VCT plc's company bio, employee growth, exchange listings and data sources
- Name: Seneca Growth Capital VCT plc
- Ticker: SVCT
- Exchange: LSE
- Founded: 2001
- Industry: Asset Management and Custody Banks
- Sector: Diversified Financials
- Market Cap: UK£8.605m
- Shares outstanding: 15.46m
- Website: https://www.senecavct.co.uk
- Seneca Growth Capital VCT plc
- 12 The Parks
- WA12 0JQ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HYG||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||GBP||Apr 2002|
|SVCT||LSE (London Stock Exchange)||New B Shares||GB||GBP||Sep 2018|
Seneca Growth Capital VCT plc is a fund of Seneca Partners Limited. The fund specializes in growth capital investments. It invests in emerging biotechnology companies. It prefers to invest in unquoted and quoted medtech companies. The fund seeks to invest in the United Kingdom and internationally. It typically invest in companies with sales greater than £10 million ($11.90 million), gross margin greater than 50% and operating margin greater than 10%, and breakeven with annual sale of less than £3 ($3.57 million).
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/31 03:16|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.